This session addressed the complexities of left main PCI, focusing on managing hemodynamic uncertainty in high-risk interventions, advanced techniques such as ultra-low contrast rota-tripsy PCI, precise stent positioning, and pragmatic approaches to CHIP cases, emphasizing contrast-sparing strategies and best practice balancing.

Explore a multi-device strategy for tackling complex calcified coronary lesions in this session. It includes case studies on left main trifurcation stenting, resistant calcified nodules treated with orbital atherectomy, severe restenosis, and critical calcifications in challenging anatomies, showcasing advanced techniques for plaque modification and lesion management.

This session highlights innovative transcatheter aortic valve implantation (TAVI) approaches for treating aortic regurgitation, focusing on off-label uses and complex cases. It features high-risk patient interventions, including nonagenarian patients, and strategies to manage severe non-calcific native valve regurgitation with balloon-expandable valves.

This session explores alternative access strategies for Transcatheter Aortic Valve Implantation (TAVI) when the transfemoral route is not feasible. It covers complex scenarios including transcaval TAVI complications, transaxillary approaches, management of extra-large annuli with peripheral artery disease, and innovative transcarotid valve-in-valve procedures.

Femoral artery pseudoaneurysm is a known complication following cardiac catheterization. Rarely, expansion of the pseudoaneurysm can occur and is often catastrophic. We describe a unique method employed by our centre to deal with such a complication.

Thanks to the contribution of a team of interventional cardiologists from around the globe, get the international perspective on Late-breaking Clinical Trials and Science released at TCT 2024 - check out the list below.

Transcatheter aortic valve implantation (TAVI) offers an effective, less invasive therapeutic alternative to surgical aortic valve replacement in patients with symptomatic, severe aortic stenosis. Although TAVI is demonstrated to be superior to medical therapy or surgery in patients who are at prohibitive or high risk for...

Yohei Ohno provides his takeaways from the results of the Evolut Low Risk trial which was presented by Michael J. Reardon during the ACC.25 in Chicago.

Jonathan Curio provides his take on the PROTECTED TAVR study which was presented by Samir R. Kapadia at TCT 2022. The aim was to evaluate whether TAVR with cerebral embolic protection would reduce the rate of clinical stroke in transfemoral TAVR.

Luigi Biasco provides his take on the clinical trial presented by John K. Forrest from Yale University School of Medicine, New Haven, Connecticut, USA during the 2023 ACC/WCC annual congress held in New Orleans, Louisiana.